| mavoglurant (STP7) / STALICLA |
Parkinson disease-1: AFQ056 in Phase III development for the treatment of Parkinson's disease levodopa-induced dyskinesia. |
|
|
| Ongoing | 3 | 0 | RestOfWorld | mavoglurant (AFQ056) | Novartis | Parkinson's Disease | | | | |
NCT06136195: Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers |
|
|
| Not yet recruiting | 2 | 63 | US | Mavoglurant, STP7 | Yale University, National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Alcohol Consumption, Heavy Drinker, Alcohol Use Disorder (AUD) | 05/26 | 05/26 | | |
2010-019353-18: Two-period, single-dose pharmacokinetic study in male adolescent patients with Fragile X Syndrome (FXS). |
|
|
| | 1 | | NA | AFQ056, AFQ056, | Novartis Pharma Services AG, Novartis Pharma Services AG | Fragile X Syndrome | | | | |
| Completed | 1 | 34 | US | Mavoglurant, Placebo | Yale University, National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Alcohol Drinking | 07/23 | 07/23 | | |
| Recruiting | 1 | 20 | US | STP7 (mavoglurant) or Placebo, Cocaine, Saline infusion | Stalicla SA, National Institute on Drug Abuse (NIDA) | Cocaine Use Disorder | 09/24 | 09/24 | | |
NCT05203965: Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant |
|
|
| Recruiting | 1 | 80 | US | Mavoglurant (AFQ056), Placebo | Yale University, National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Familial Alcoholism Vulnerability | 06/25 | 06/25 | | |